Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish
Stock Performance and Recent Rally Ventyx Biosciences has been one of 2025’s biggest small-cap biotech movers. The Nasdaq-listed stock jumped sharply on Oct. 22 after hours, when the company announced the positive Phase 2 data. On Oct. 22 regular trading, VTYX ended at $3.86 (up +2.66% that day) marketbeat.com, but in electronic after-hours trading it skyrocketed roughly 85–90%, touching the low $7’s marketbeat.com benzinga.com. By early Oct. 23 the stock was quoting around $3.86 (as markets reopened), reflecting profit-taking after the spike. Over the past six months, the stock had already climbed over 230%, driven by pipeline optimism benzinga.com. Analysts